1 to 6 of 116 results
A new experimental vaccine developed in Leiden targets lung cancer cells that evade the immune system. The approach could make immunotherapy more effective for patients for whom existing treatments prove ineffective.
Two research teams from Leiden University have been awarded HTSM funding for groundbreaking technological research with applications in areas such as quality control and medical imaging.
For the first time in the Netherlands, a patient with a serious autoimmune disease has been treated with CAR-T cell therapy. With this, the LUMC has achieved an important medical milestone in the development of innovative treatments outside of oncology.
Read more about Medical milestone: CAR-T used to treat autoimmune disease
Another major scientific breakthrough has been achieved in the Leiden region. Together, Mimetas and the Leiden Academic Centre for Drug Research (LACDR) have developed an advanced "artery-on-a-chip" model.
Three research teams from Leiden University have recently been awarded prestigious NWO grants. The funding will enable groundbreaking fundamental research in areas such as drug development and cosmic particles.
Researchers at the LACDR at LUMC have developed a synthetic alternative to antibodies that is more stable, cheaper and easier to produce. This discovery could radically change the future of drug development and administration.
Read more about Artificial “antibodies”: the future of drug development?
